Glenmark Pharmaceuticals’ subsidiary, Glenmark Life Sciences, is being considered for a majority stake sale, with several private equity firms expressing preliminary interest. Glenmark Life Sciences specializes in the development and manufacture of active pharmaceutical ingredients (APIs). The final decision on the sale has not yet been made, and the process is still ongoing. The potential for a sale of the API subsidiary has been a topic of discussion for some time.
Today: December 2, 2023